Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Pd-1 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT04631731
What this trial is testing

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

Who this might be right for
Lung Cancer, Nonsmall CellRenal Cell CarcinomaMelanoma+4 more
Western Sydney Local Health District 200
Early research (Phase 1)Study completedNCT03551782
What this trial is testing

Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostatic Neoplasms
Janssen Research & Development, LLC 33
Testing effectiveness (Phase 2)Looking for participantsNCT06492005
What this trial is testing

A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd. 160
Testing effectiveness (Phase 2)Study completedNCT04691388
What this trial is testing

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Who this might be right for
NSCLC
Zhejiang Cancer Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT06151743
What this trial is testing

Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma

Who this might be right for
Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University 32
Not applicableNot Yet RecruitingNCT07062484
What this trial is testing

A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma

Who this might be right for
Lung Metastatic Nasopharyngeal Carcinoma
Sichuan Cancer Hospital and Research Institute 600
Post-approval studies (Phase 4)Looking for participantsNCT06311929
What this trial is testing

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

Who this might be right for
HCC
Chen Xiaoping 300
Early research (Phase 1)Looking for participantsNCT05422794
What this trial is testing

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Triple-Negative Breast Carcinoma+2 more
National Cancer Institute (NCI)
Early research (Phase 1)Study completedNCT03525795
What this trial is testing

ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Constellation Pharmaceuticals 24
Not applicableLooking for participantsNCT05139706
What this trial is testing

Montreal Immune-Related Adverse Events (MIRAE) Study

Who this might be right for
CancerImmune System DisorderInflammatory Reaction+1 more
Sir Mortimer B. Davis - Jewish General Hospital 1,000
Early research (Phase 1)Ended earlyNCT05757492
What this trial is testing

Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorNon-Small Cell Lung CancerHepatocellular Carcinoma
Coherus Oncology, Inc. 22
Not applicableUnknownNCT06423144
What this trial is testing

PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 150
Testing effectiveness (Phase 2)Looking for participantsNCT07277764
What this trial is testing

Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)

Who this might be right for
Nasopharyngeal Carcinoma (NPC)Recurrent Nasopharyngeal Neoplasms
Jiangxi Provincial Cancer Hospital 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06573398
What this trial is testing

Radiotherapy With Sequential Chemotherapy Combined With PD-1 Inhibitor and Thymalfasin for BRPC

Who this might be right for
Carcinoma, Pancreatic Ductal
Ruijin Hospital 20
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Testing effectiveness (Phase 2)UnknownNCT05007145
What this trial is testing

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Who this might be right for
Esophageal NeoplasmsEsophageal Squamous Cell Carcinoma
Fujian Cancer Hospital 92
Testing effectiveness (Phase 2)Ended earlyNCT05239182
What this trial is testing

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Anwaar Saeed 7
Not applicableUnknownNCT05418660
What this trial is testing

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer
University of Milano Bicocca 300
Testing effectiveness (Phase 2)Enrolling By InvitationNCT07618624
What this trial is testing

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression

Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaHead and Neck Cancer
Sun Yat-sen University 42
Large-scale testing (Phase 3)Study completedNCT03374488
What this trial is testing

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 84
Next Page
57